Milademetan is a Small Molecule owned by Rain Therapeutics, and is involved in 9 clinical trials, of which 5 were completed, 3 are ongoing, and 1 is planned.
Milademetan inhibits murine double minute 2 (MDM2). MDM2, a zinc finger protein, is a negative regulator of the p53 pathway; often over-expressed in cancer cells. It has been implicated in cancer cell proliferation and survival. The drug candidate binds to MDM2, thereby preventing the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored, which may result in the restoration of p53 signaling and thus the p53-mediated induction of tumor cell apoptosis.
The revenue for Milademetan is expected to reach a total of $820m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Milademetan NPV Report.
Milademetan was originated by Rigel Pharmaceuticals and is currently owned by Rain Therapeutics.
Milademetan is under development for the treatment of advanced solid tumors, liposarcoma, dedifferentiated liposarcoma, refractory or relapsed acute myeloid leukemia (AML), pancreatic cancer, lung cancer, breast cancer, biliary tumor and malignant pleural mesothelioma (MPM). The drug candidate is administered orally as a capsule. The drug candidate acts by targeting murine double minute 2 (MDM2) protein.
It was also under development for acute lymphocytic leukemia (ALL), Merkel cell carcinoma, multiple myeloma, soft tissue sarcoma, lymphomas, chronic myelogenous leukemia (CML) and myelodysplastic syndrome.
Rain Therapeutics Overview
Rain Therapeutics is a biotechnology company that discovers, develops and translates cancer therapies. It is investigating its lead product candidate milademetan, an oral small molecule, inhibitor of mouse double minute 2 (MDM2) to treat well-differentiated (WD) and dedifferentiated (DD) liposarcoma, Merkel cell carcinoma, amplified and advanced solid tumors. The company is also evaluating a RAD52 inhibiting program targeting homologous recombination deficiencies (HRD+) and loss of function of several pathway constituents including BRCA1/2, PALB2 in breast, prostate, pancreatic, ovarian and other tumors. Rain Therapeutics is headquartered in Newark, California, the US.
The operating loss of the company was US$51.5 million in FY2021, compared to an operating loss of US$19 million in FY2020. The net loss of the company was US$51.4 million in FY2021, compared to a net loss of US$21.1 million in FY2020.
Quick View – Milademetan
|Highest Development Stage|